Therapy Area
EFISCIENS is involved in numerous therapeutic areas to revive treatments and protocols.
For several years, the company has been developing, acquiring and forming alliances in the following disciplines: Oncology, Transplantation, Radiotherapy and Supportive Care.
Our laboratory also has interests in Emergency Care, Endocrinology and Psychiatric Diseases.
EFISCIENS is committed to excellence and is dedicated to improving and/or reintroducing products in each of these therapeutic areas.
EFISCIENS provides effective care for patients preparing for bone marrow transplant. Thioplex is the most effective alkylating agent in first-line therapy for guarantee transplant protocol.
​
Last clinical studies definitively show that all lipid formulations of invasive fungal infections are effective in prophylaxis to patients with acute myelogenous leukaemia and myelodysplastic syndromes undergoing induction chemotherapy.
​
Used in the prophylaxis of invasive fungal infections in patients under transplant protocol. EFISCIENS is one of the best alternative to supply supportive care products with two effective products in first-line therapy for transplants.
Our Laboratory is at the forefront of developing new treatments for patients suffering from different types of cancer, including small cell lung, non-hodgkin's lymphoma, mycosis fungicides and para-psoriasis.
These agents are typically alkylating, exerting a potent cytotoxic action that curtails the rapid spread of cancer celles or serves as a vital component in chemotherapy protocols.
Our laboratory provides a leading antiemetic drug. It is an essential component of any chemotherapy patients's care pathway.
Our laboratory provides care support to patients suffering from tachycardia to eclampsia even vital prognostic engaged.
-Emergency treatment of junctional tachycardia is effective and is also an excellent diagnostic aid for wide or narrow complex tachycardia.
Emergency treatment is required for sympathetic tachycardia and certain forms of cardiac arrhythmia.
-Pre-eclampsia is a serious health threat that can lead to life-threatening complications in breastfeeding mothers.
We will perform to preserve access to emergency care and ongoing therapeutic treatment. Our goal is to ensure a cure for the benefit of every life on Earth.
Our laboratory treats patients with Addison's disease, a rare and chronic condition caused by adrenal gland failure.
​
EFISCIENS is committed to supporting patients suffering from Graves-Basedow's disease. This is an autoimmune disorder of the endocrine system.
The stimulation attacks the thyroid gland, and it is the most common cause of hyperthyroidism.
EFISCIENS supports patients suffering from the side effects of chemotherapy and/or radiotherapy.
The most common side effects are severe pain due to changes in the gums, parotid or salivary glands, xerostomia, Sjogren's syndrome, burns, oesophageal pain or radiation dermatitis.
EFISCIENS offers a new range of products to relieve patients exposed to such adverse effects and them guaranteeing a better quality of life to pursue their therapies.
EFISCIENS should be delighted to have available a non-specific, non-reversible, antidepressant, psychostimulant, MAO inhibitor that is effective in the treatment of various anxiety disorders (panic attacks, phobia even post-traumatic stress) and/or depressive disorders.
The availability of an antipsychotic in our laboratory is a real opportunity to improve the range of pharmacological strategies available.
The weekly dose favilitates dosage adjustment easier, and the oral administration is much more acceptable than any treatment by injection.
In this context, there is no doubt that our antipsychotic should occupy an important place among the specialist treatments prescribed for schizophrenia spectrum disorders.
​
REVIVING THERAPIES.....
